Login / Signup

Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer.

Shijia ZhangDaniel F PeaseAmit A KulkarniManoj KumarRyan M ShanleyBeibei XuShilvi P JoshiManish R Patel
Published in: Clinical Medicine Insights. Oncology (2021)
The clinical benefit of ICIs appears to persist in a real-world population of relatively older age, including those with poor PS and pre-existing autoimmune diseases. ECOG PS of 0 to 1 and BMI ⩾ 25 kg/m2 were independently associated with improved OS.
Keyphrases
  • body mass index
  • physical activity
  • type diabetes
  • metabolic syndrome
  • open label
  • weight gain
  • skeletal muscle
  • study protocol